medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2022, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2022; 67 (2)

Controversies in the management of precocious puberty

González BI, López LAP, González MAP, Arguinzoniz VSL

Language: Spanish
References: 78
Page: 100-108
PDF size: 331.42 Kb.


ABSTRACT

Gonadotropin-releasing hormone analogs have been the treatment of choice for central precocious puberty for many years. Its main objectives are to recover the growth potential compromised by the premature fusion of the growth plates and to avoid psychosocial sequelae derived from early puberty. They are generally effective, safe, and well tolerated. However, many of the studies reporting its benefits are inconsistent. In addition, there are also some controversies about the potential negative effects of analogs on weight and metabolic profile, bone mineral density and reproductive function in adult life. The objective of this review was to analyze the long-term positive and negative effects of gonadotropin-releasing hormone analogs, body composition, bone mineral density and reproductive function in patients with central precocious puberty.


REFERENCES

  1. Chan YM, Feld A, Jonsdottir-Lewis E. Effects of the timing of sex-steroid exposure in adolescence on adult health outcomes. J Clin Endocrinol Metab. 2019; 104 (10): 4578-4586.

  2. Farello G, Altieri C, Cutini M, Pozzobon G, Verrotti A. Review of the literature on current changes in the timing of pubertal development and the incomplete forms of early puberty. Front Pediatr. 2019; 7: 147.

  3. Delemarre-van de Waal HA. Regulation of puberty. Best Pract Res Clin Endocrinol Metab. 2002; 16 (1): 1-12.

  4. Forest MG, Cathiard AM, Bertrand JA. Evidence of testicular activity in early infancy. J Clin Endocrinol Metab. 1973; 37: 148-151.

  5. Kuiri-Hanninen T, Kallio S, Seuri R, Tyrvainen E, Liakka A, Tapanainen J et al. Postnatal developmental changes in the pituitary- ovarian axis in preterm and term infant girls. J Clin Endocrinol Metab. 2011 96 (11): 3432-3439.

  6. Kirivanta P, Kuiri-Hanninen T, Saari A, Lamidi ML, Dunkel L, Sankilampi U. Transient postnatal gonadal activation and growth velocity in infancy. Pediatrics. 2016; 138: e20153561.

  7. Sultan C, Gaspari S, Maimoun L, Kalfa N, Paris F. Disorders of puberty. Best Pract Res Clin Obstet Gynaecol. 2018; 48: 62-89.

  8. Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2016; 174: R79-R87.

  9. Terasawa E, Fernandez DL. Neurobiological mechanisms of the onset of puberty in primates. Endocr Rev. 2001; 22 (1): 111-151.

  10. Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics. 2009; 123: 84-88.

  11. Mul D, Fredriks AM, van Buuren S, OostdijkW, Verloove-Vanhorick SP, Wit JM. Pubertal development in The Netherlands 1965-1997. Pediatr Res. 2001; 50: 479-486.

  12. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008; 358: 2366-2377.

  13. Dixon J, Ahmed S. Precocious puberty. Paediatrics and Child Health. 2007; 17: 343-348.

  14. Berberoglu M. Precocious puberty and normal variant puberty: definition, etiology, diagnosis and current management. J Clin Res Pediatr Endocrinol. 2009; 1 (4): 164-174.

  15. Kumar M, Mukhopadhyay S, Dutta. Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: an Indian perspective. Indian J Endocr Metab. 2015; 19 (2): 228-235.

  16. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update. 2004; 10 (2): 135-147.

  17. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol. 2002; 56: 129-148.

  18. Bulcao Macedo D, Nahime Brito V, Latronico AC. New causes of central precocious puberty: the role of genetic factors. Neuroendocrinology. 2014; 100: 1-8.

  19. Schneider Aguirre R, Eugster E. Central precocious puberty: From genetics to treatment. Best Pract Res Clin Endocrinol Metab. 2018; 32 (4): 343-354.

  20. Biro FM, Greenspan LC, Galvez MP, Pinney SM, Teitelbaum S, Windham GC, Deardorff J, Herrick RL, Succop PA, Hiatt RA et al. Onset of breast development in a longitudinal cohort. Pediatrics. 2013; 132: 1019-1027.

  21. Christoforidis A, Stanhope R. Girls with gonadotrophin-dependent precocious puberty: do they all deserve neuroimaging. J Pediatr Endocrinol Metab. 2005; 18 (9): 843-844.

  22. Mogensen SS, Aksglaede L, Mouritsen A, Sorensen K, Main KM, Gideon P et al. Pathological and incidental findings on brain MRI in a single-center study of 229 consecutive girls with early or precocious puberty. PLoS One. 2012; 7 (1): e29829.

  23. De Vries L, Horev G, Schwartz M, Phillip M. Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol. 2006; 154 (6): 891-898.

  24. Sathasivam A, Rosenberg HK, Shapiro S, Wang H, Rapaport R. Pelvic ultrasonography in the evaluation of central precocious puberty: comparison with leuprolide stimulation test. J Pediatr. 2011; 159 (3): 490-495.

  25. Binay C, Simsek E, Bal C. The correlation between GnRH stimulation testing and obstetric ultrasonographic parameters in precocious puberty. J Pediatr Endocrinol Metab. 2014; 27 (11-12): 1193-1199.

  26. Krishna KB, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, Charmandari E, Lee PA. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019; 91 (6): 357-372.

  27. Kim EY. Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty. Korean J Pediatr. 2015; 58 (1): 1-7.

  28. Soliman AT, De Sanctis V. An approach to constitutional delay of growth and puberty. Indian J Endocrinol Metab. 2012; 16 (5): 698-705.

  29. Willemsen RH, Elleri D, Williams RM, Ong KK, Dunger DB. Pros and cons of GnRHa treatment for early puberty in girls. Nat Rev Endocrinol. 2014; 10: 352-363.

  30. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012; 13 (11): 1141-1151.

  31. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000; 13 (Suppl 1): 723-737.

  32. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009; 123: e752-e762.

  33. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981; 52 (2): 370-372.

  34. Fujisaki A, Kondo Y, Goto K, Morita T. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature. Int J Urol. 2012; 19 (1): 81-84.

  35. Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl. 2008; 10 (4): 525-534.

  36. Mul D, Hughes HI. The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 2008; 159: S3-S8.

  37. Lazar L, Phillip M. Pubertal disorders and bone maturation. Endocrinol Metab Clin North Am. 2012; 41 (4): 805-825.

  38. Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinoly. 2002; 56 (3): 297-302.

  39. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinolo Metab. 2008; 93 (1): 190-195.

  40. Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol. 2011; 27 (8): 524-528.

  41. Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr. 1998; 87 (5): 521-527.

  42. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007; 92 (9): 3483-3489.

  43. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res. 2002; 58 (19: 1-7.

  44. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, Satoh M, Kugu K. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab. 2005; 90 (3): 1371-1376.

  45. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol. 1999; 141 (2): 140-144.

  46. Bajpai A, Sharma J, Kabra M, Gupta AK, Menon PS. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. Indian Pediatr. 2002; 39 (7): 633-639.

  47. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999; 84: 4583-4590.

  48. Jung MK, Song KC, Kwon AR, Chae HW, Kim DH, Kim HS. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone. Ann Pediatr Endocrinol Metab. 2014; 19: 214-219.

  49. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001; 86 (10): 4711-4716.

  50. Liang Y, Wei H, Li J, Hou L, Zhang J, Wu W, Ying Y, Luo X. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty. J Pediatr Endocrinol Metab. 2015; 28: 839-846.

  51. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res. 1997; 47: 54-61.

  52. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr. 1998; 157: 363-367.

  53. Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr. 2000; 137: 819-825.

  54. Nabhan ZM, Feezle LK, Kunselman AR, Johnson NB, Lee PA. Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. J Pediatr Endocrinol Metab. 2009; 22: 309-316.

  55. Gillis D, Karavani G, Hirsch HJ, Strich D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr. 2013; 163: 532-536.

  56. Brito VN, Latronico AC, Cukier P, Teles MG, Silveira LF, Arnhold IJ, Mendonca BB. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab. 2008; 93 (7): 2662-2669.

  57. Wang M, Zhang Y, Lan D, Hill JH. The efficacy of GnRH Alone or in Combination with rhGH for treatment of chinese children with central precocious puberty. Nature-Scientific Reports. 2016; 6: 24259.

  58. Massart F, Federico G, Harrell JC, Saggese G. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Neuroendocrinology. 2009; 90: 307-314.

  59. Aguiar AL, Couto-Silva AC, Vicente EJ, Freitas IC, Cruz T, Adan L. Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues. J Pediatr Endocrinol Metab. 2006; 19 (11): 1327-1334.

  60. Wagner S IV, Abin MA, Pfaffle RW, Hiemisch A, Sergeyev E, Korner A, Kiess W. Effects of obesity on human sexual development. Nat Rev Endocrinol. 2012; 8: 246-254.

  61. Lazar L, Lebenthal Y, Yackobovitch-Gavan M, Shalitin S, de Vries L, Phillip M, Meyerovitch J. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab. 2015; 100 (4): 1445-1451.

  62. Lee SJ, Yang EM, Seo JY, Kim CJ. Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty. Chonnam Med J. 2012; 48 (1): 27-31.

  63. Yang WJ, Ko KH, Lee KH, Hwang IT, Oh YJ. The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017; 22 (1): 49-54.

  64. Yoon JW, Park HA, Lee J, Kim JH. The influence of gonadotropin realising hormone agonist on anthropopetric change in girls with central precoucious puberty. Korean J Pediatr. 2017; 60 (12): 395-402.

  65. Van der Sluis et al. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab. 2002; 87 (2): 506-512.

  66. Gu Q, Luo Y, Ye J, Shen X et al. Comparative efficacy and safety of three current clinical treatments for girls with central precocious puberty: a network metaanalisis. Endocrine Practice. 2019; 25 (7): 717-728.

  67. Faienza MF, Brunetti G, Acquafredda A, Delvecchio M, Lonero A, Gaeta A et al. Metabolic outcomes, bone health, and risk of polycystic ovary syndrome in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogues. Horm Res Paediatr. 2017; 87 (3): 162-169.

  68. Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab. 1998; 83 (2): 370-373.

  69. Park HK, Lee HS, Ko JH, Hwang IT, Lim JS, Hwang JS. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf). 2012; 77: 743-748.

  70. Assa A, Weiss M, Aharoni D, Mor A, Rachmiel M, Bistritzer T. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist. J Pediatr Endocrinol Metab. 2011; 24 (7-8): 505-510.

  71. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, Papaefstathiou A, Lalioti N, Kanaka-Gantenbein C, Piaditis G et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010; 95: 109-117.

  72. Tung YC, Lee JS, Tsai WY, Hsiao PH. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. J Formos Med Assoc. 2007; 106 (10): 826-831.

  73. Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr. 2000; 159 (5): 369-374.

  74. Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab. 1999; 84 (1): 44-49.

  75. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol. 2004; 61: 626-634.

  76. Silverman LA, Neely EK, Kletter GB, Lewis K, Chitra S, Terleckyj O, Eugster EA. Long-term continuous suppression with once yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab. 2015; 100 (6): 2354-2363.

  77. Jay N, Mansfield MJ, Blizzard RM, Crowley WF Jr, Schoenfeld D, Rhubin L, Boepple PA. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 1992; 75 (3): 890-894.

  78. Lazar L, Meyerovitch J, de Vries L, Phillip M, Lebenthal Y. Treatedand untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol (Oxf). 2014; 80 (4): 570-576.




2020     |     www.medigraphic.com